December 23, 2004: Baxter Announces European Union Expanded Approval of ADVATE For Use in Children With Haemophilia A Less Than Six Years Old
December 9, 2004: Baxter Suspends Enrollment in European Clinical Trial for PreFluCel
November 24, 2004: Baxter Highlights Programs at National Hemophilia Foundation Annual Meeting to Help Hemophilia Community Address Critical Issues
November 18, 2004: President of Baxter's Medication Delivery Business to Retire
November 17, 2004: Baxter Names Robert M. Davis Treasurer
November 16, 2004: Baxter Declares Annual Dividend
November 8, 2004: Baxter and National Hemophilia Foundation (NHF) Announce Awards Under NHF Clinical Fellowship Program
November 1, 2004: Baxter Announces Promotion of Mary Kay Ladone to Vice President of Investor Relations
October 29, 2004: Baxter Releases First Round of Findings from Unique Long-Term Chronic Kidney Disease Research Program
October 25, 2004: Study Shows Alpha1- Proteinase Inhibitor Augmentation Therapy May Improve Outcomes, Lower Costs for Hereditary Emphysema
October 22, 2004: Baxter Submits Regulatory Application to Japanese Minister of Health Seeking Approval of Advate for Hemophilia A
October 21, 2004: Baxter Reports Third Quarter Results With EPS of $0.42, In Line With Expectations
October 14, 2004: Baxter and Cerus Announce Closure of Transaction with BioOne Corporation
September 1, 2004: Baxter International Inc. Names Albert Stroucken to Board of Directors
August 16, 2004: Baxter Receives Positive Opinion from French Transparency Commission for Reimbursement of ADVATE for Haemophilia A
August 12, 2004: Pharmacy Society Adds New Self-Assessment Tool to Compounding Resource Center
August 3, 2004: Baxter Announces U.S. Food and Drug Administration Approval for Generic Version of Common Anti-Fungal, Fluconazole
August 2, 2004: Baxter Appoints Joy Amundson as President of its BioScience Business
July 29, 2004: Baxter Expands Sustainability Reporting with Launch of New Website
July 29, 2004: Baxter and Cerus Enter Agreement with Asian Partner for Commercialization of INTERCEPT Blood System for Platelets
July 22, 2004: Baxter Reports Second Quarter Results
July 13, 2004: New System for Collecting Red Blood Cells from Donors Allows Blood Services to Better Meet Transfusion Needs
June 21, 2004: Baxter Names John Greisch Senior Vice President and Chief Financial Officer
June 7, 2004: Baxter Announces Change in Leadership of Investor Relations
May 27, 2004: Baxter Receives FDA Warning Letter on Promotional Materials for ADVATE
May 25, 2004: Data Presented Show Treatment with Baxter´s ARALAST May Positively Impact Life Expectancy in Patients with Hereditary Emphysema
May 17, 2004: Baxter Healthcare and American Association of Critical-Care Nurses Announce New Patient Safety Award
May 4, 2004: New CEO Emphasizes Commitment to Financial Discipline and Value Creation at Baxter´s Annual Stockholder Meeting
April 22, 2004: Baxter Reports First Quarter Sales Growth of 11 Percent and EPS of $0.31
April 19, 2004: Baxter´s Board of Directors Announces Appointment of Robert L. Parkinson, Jr. as Chairman and CEO
March 29, 2004: Baxter and InterMune Sign Agreement for the Co-Promotion of ARALAST in the Pulmonology Arena
March 16, 2004: Baxter Announces Resignation of Thomas J. Sabatino, Jr. as Senior Vice President and General Counsel
March 3, 2004: Baxter Receives Marketing Authorisation from the European Commission for ADVATE to Treat Haemophilia A
March 1, 2004: Baxter International Foundation Awards $3.6 Million in 2003 to More Than 220 Organizations in 25 Countries
February 27, 2004: Baxter and Arriva Pharmaceuticals Complete First Clinical Trial Evaluating the Safety and Tolerability of Nebulized Recombinant Alpha 1-Antitrypsin
February 02, 2004: Baxter Grants European Rights to Teva for LEUPROMAXX
January 29, 2004: Baxter Announces Fourth Quarter and Full Year 2003 Results
January 26, 2004: Baxter Announces Harry Kraemer to Resign as Chairman and CEO
January 22, 2004: Phoebe Putney Memorial Hospital of Albany, Georgia Wins Foster G. McGaw Prize for Excellence in Community Service